Menlo Therapeutics

Developer of serlopitant drugs for the treatment of severe, chronic pruritus

placeMenlo Park, California, United States calendar_todayFounded 2011 groups40 employees language menlotherapeutics.com

Registered entities

Innovation

8 patent families (3 granted) — focus: Human necessities; filing pace slowing. Cited 2,130 times.

YearFilings
20163
20173
20185
20194
20207
20212

Investor mix

12 investors on record; lead investors include VenBio.

Investor typeCountShare
Venture capital867%
Private equity217%
Other / undisclosed217%
Coming soon